Tivic Health Files 10-Q, Details Q1 2025 Operations
Ticker: TIVC · Form: 10-Q · Filed: May 15, 2025 · CIK: 1787740
Sentiment: neutral
Topics: 10-Q, financials, agreements, stock
TL;DR
TIVC 10-Q filed: Q1 2025 financials out, stock and agreements detailed.
AI Summary
Tivic Health Systems, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations. Key disclosures include details on its common stock, restricted stock units, and various agreements such as securities purchase agreements and license agreements, some of which were executed on February 11, 2025.
Why It Matters
This filing provides investors with an update on Tivic Health's financial health and operational activities for the first quarter of 2025, including details on stock and agreements.
Risk Assessment
Risk Level: medium — The filing is a standard 10-Q, but the company's specific financial performance and market position could introduce medium risk.
Key Numbers
- 0.0588 — Expected Dividend Rate (Indicates a potential dividend rate for common stock.)
- 0.01 — Measurement Input (A specific input value used in financial measurements.)
Key Players & Entities
- Tivic Health Systems, Inc. (company) — Filer of the 10-Q
- 0000950170-25-072752 (other) — Accession Number for the filing
- 20250331 (date) — Period of report
- February 11, 2025 (date) — Date of key agreements
FAQ
What was Tivic Health Systems, Inc.'s revenue for the quarter ending March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ending March 31, 2025.
What is the nature of the 'Securities Purchase Agreement' mentioned?
The filing mentions 'Securities Purchase Agreement' in the context of transactions occurring between January 1, 2025, and March 31, 2025, with a specific agreement dated February 11, 2025.
What is the significance of the 'License Agreement' dated February 11, 2025?
The 'License Agreement' dated February 11, 2025, is mentioned alongside the 'File USBLA With FDA And Achieve FDA Approval For Use As A Vaccine Adjuvant' objective.
What are the key financial instruments or securities discussed in the filing?
The filing discusses 'Common Stock' and 'Restricted Stock Units (RSU)'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Tivic Health Systems, Inc. (TIVC).